|
Oxford BioMedica PLC on Monday said it expects to report a jump in revenue in the first half of the year as its order book more than doubled. The Oxford, England-based cell and gene therapy contract development and manufacturing company said it expects to report revenue between £70 million and £73 million for the six months to the end of June, up by between 38% and 44% from £51 million a year ago. Oxford BioMedica said it signed £149 million new orders during the first half of the year, more than doubled from £56 million at the same point last year. The company reiterated its full-year guidance for revenue between £160 million and £170 million. This would be up 24% to 32% from £128.8 million in 2024. It said more than £165 million of 2025 revenue is covered by contracted client orders, compared to £103 million for the same period last year. This provides ‘clear visibility for the remainder of the year’, the company said. Revenue phasing in the second half includes an increase in manufacturing activity for clients preparing for commercial launch, it noted. Oxford BioMedica said it expects low-single-digit operating earnings before interest, tax, depreciation and amortisation profitability, on a constant currency basis, for the full year. The revenue backlog stood at £222 million on June 30, compared to £150 million at the end of 2024. ‘OXB is seeing increased client demand from existing and new clients, particularly among clients looking to accelerate execution of late-stage lentiviral programmes,’ it noted. The company said it is proceeding with planned capacity management initiatives to allow for current and expected growth. This includes an increase in manufacturing capacity at its UK sites, to be completed by the first half of 2026, as well as expanding UK lab capacity for development services to support late-stage client programme activities. It has also started transferring its adeno-associated virus vector platform to its sites in France. ‘With our multi-vector, multi-site model now fully in place, our strong operational and commercial progress continued in the first half of the year, reflecting both our execution capabilities and the growing trust in OXB as a leading cell and gene [contract development and manufacturing organisation] partner,’ said Chief Executive Officer Frank Mathias. ‘Our order book has more than doubled year-on-year, including notable growth in late-stage programme activity, demonstrating strong demand for our services and providing long-term revenue visibility. As we expand capacity to meet this growing demand, we remain focused on operational excellence and cost discipline.’ Shares in Oxford BioMedica were up 6.0% at 406.00 pence in London on Monday morning. It expects to report its full interim results on September 23. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
